LENALIDOMIDE: RECENT ARMAMENTARIUM IN MANAGEMENT OF MULTIPLE MYELOMA
Lenalidomide is an analogue of thalidomide. It is an oral immunomodulatory compound with potent activity and different toxicity profile than thalidomide. Lenalidomide is one of the novel drug agents used to treat multiple myeloma. Multiple myeloma (MM) is a B cell malignancy characterized by excess monotypic plasma cells in the bone marrow. Lenalidomide in combination with dexamethasone is one of the most promising MM novel treatment options. It induces at least additive direct cytotoxicity in multiple myeloma cells. The lenalidomide has possibility of being used as an adjuvant in support of more specific immunotherapeutic interventions including cancer chemotherapy, anticancer vaccines and adoptively transferred cells which warrants further investigation.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).